Abstract
Intravascular brachytherapy with gamma sources has been proved to prevent in‐stent restenosis in recent clinical trials. Beta sources are also being investigated. The intravascular use of radioactive sources has raised theoretical and logistic problems and renewed the interest in teletherapy for the treatment and prevention of restenosis. We review the literature published on the use of teletherapy in animal models and compare it to brachytherapy from biological and logistic points of view. Developing technologies for stereotactic radiotreatment of moving targets may offer new solutions and are being studied.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
